25TFM-NBOMe (also known as NBOMe-2C-TFM, 2C-TFM-NBOMe, and Cimbi-138) is a derivative of the phenethylamine hallucinogen 2C-TFM, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent partial agonist for the 5-HT2A receptor, though its relative potency is disputed, with some studies finding it to be of lower potency than 25I-NBOMe, while others show it to be of similar or higher potency, possibly because of differences in the assay used. 2C-TFM-NB2OMe can be taken to produce psychedelic effects similar to 2C-I-NB2OMe and 2C-D-NB2OMe.
Legality
United Kingdom
This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.
See also
- DOTFM
- TFMFly
- 2CBCB-NBOMe (NBOMe-TCB-2)
- 2CBFly-NBOMe (NBOMe-2CB-Fly)
- 25C-NBOMe (NBOMe-2CC)
- 25B-NBOMe (NBOMe-2CB)
- 25D-NBOMe (NBOMe-2CD)
- 25I-NBOMe (NBOMe-2CI)
- 25I-NBMD (NBMD-2CI)
- 25B-NBOH
- 25I-NBOH (NBOH-2CI)
- 25I-NBF (NBF-2CI)
References
